Immix Biopharma Management
Management criteria checks 3/4
Immix Biopharma's CEO is Ilya Rachman, appointed in Jan 2012, has a tenure of 13.08 years. total yearly compensation is $1.13M, comprised of 39.5% salary and 60.5% bonuses, including company stock and options. directly owns 4.13% of the company’s shares, worth $2.28M. The average tenure of the management team and the board of directors is 3.9 years and 3.8 years respectively.
Key information
Ilya Rachman
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 39.5% |
| CEO tenure | 13.1yrs |
| CEO ownership | 4.1% |
| Management average tenure | 3.9yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Deliver On Growth Plans?
Nov 11
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Aug 12Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Nov 28Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Jul 12We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate
Mar 29Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans
Sep 13We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely
May 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$22m |
| Jun 30 2024 | n/a | n/a | -US$19m |
| Mar 31 2024 | n/a | n/a | -US$18m |
| Dec 31 2023 | US$1m | US$446k | -US$15m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$9m |
| Dec 31 2022 | US$2m | US$425k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$25m |
| Dec 31 2021 | US$397k | US$193k | -US$24m |
Compensation vs Market: Ilya's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD637.49K).
Compensation vs Earnings: Ilya's compensation has been consistent with company performance over the past year.
CEO
Ilya Rachman (51 yo)
13.1yrs
Tenure
US$1,129,881
Compensation
Dr. Ilya Rachman, MD, PhD, MBA, Co-Founder, Chairman and Chief Executive Officer at Immix Biopharma, Inc since 2012. Dr. Rachman is a pioneering physician/scientist, cell biologist and among the first to f...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.1yrs | US$1.13m | 4.13% $ 2.3m | |
| CFO & Director | 3.9yrs | US$1.13m | 1.04% $ 574.5k | |
| Chief Medical Officer & Head of Clinical Development | 3.7yrs | US$104.42k | 0% $ 0 | |
| Co-Founder | no data | no data | no data | |
| Scientific Co-Founder | 13.1yrs | no data | no data | |
| Head of Chemistry | 7.8yrs | no data | no data | |
| Chief Medical Officer of Cell Therapy | 2.1yrs | no data | no data | |
| Head of Cell Therapy Manufacturing | 2.1yrs | no data | no data |
3.9yrs
Average Tenure
62yo
Average Age
Experienced Management: IMMX's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.1yrs | US$1.13m | 4.13% $ 2.3m | |
| CFO & Director | 3.9yrs | US$1.13m | 1.04% $ 574.5k | |
| Independent Director | 3.7yrs | US$173.63k | 0.082% $ 45.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chair of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 12.1yrs | US$156.38k | 3.25% $ 1.8m | |
| Independent Director | 3.7yrs | US$180.64k | 0.17% $ 92.6k | |
| Lead Independent Director | 3.7yrs | US$429.37k | 0.64% $ 351.3k | |
| Independent Director | 5.3yrs | US$159.88k | 0.073% $ 40.2k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 3.5yrs | no data | no data |
3.8yrs
Average Tenure
60yo
Average Age
Experienced Board: IMMX's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/09 04:51 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immix Biopharma, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Soo Romanoff | Edison Investment Research |
| Arron Aatkar | Edison Investment Research |
| Robert Burns | H.C. Wainwright & Co. |